Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Synlogic (SYBX) is now available.
Synlogic, Inc. has appointed James Flynn as a new Class I Director to its Board of Directors, with his term expiring at the 2026 annual stockholders’ meeting. Flynn brings a wealth of experience as a healthcare investment specialist, with prior roles at Nerium Capital LLC, ARCA Biopharma, and Amici Capital. Concurrently, directors Mike Burgess, Lisa Kelly-Croswell, and Patricia N. Hurter have resigned, citing no disagreements with the company. Flynn’s appointment is complemented by an incentivizing stock option grant and a standard indemnification agreement.
See more insights into SYBX stock on TipRanks’ Stock Analysis page.